Altis Biosystems
Durham, US · Founded 2015 · Delaware corporation · 27 employees on LinkedIn · 7 known investors
Altis Biosystems builds RepliGut®, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling. It serves pharmaceutical and life-science researchers as an alternative to animal studies and Caco-2 cell lines, offering ready-to-use kits and custom studies.
Founders & leadership
CS
Christopher SimsExecutive
JS
Jimmy SmedleyinExecutive
SF
Samuel FranklinNamed on SEC filing
JM
Joseph McMahonNamed on SEC filing
MB
Michael BironNamed on SEC filing
SP
Swetha PeddibhotlaSenior Scientist
Board
CP
Christopher PerkinsBoard director
MD
BS
Benjamin ScruggsBoard director
SM
Susan MahonyBoard director
KC
Kevin CauseyBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 3 rounds · 2019–2025
▶$2.1MraisedApr 2025 · 9 investors · BiotechnologyRule 506(b)
▶$2.1MraisedApr 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher PerkinsDirector
- Michael DialDirector
- Christopher SimsExecutive Officer
- Benjamin ScruggsExecutive Officer, Director
- Jimmy SmedleyExecutive Officer
- Susan MahonyDirector
- Kevin CauseyDirector
- Offering amount
- $2.3M
- Amount sold
- $2.1M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedAug 2022 · 17 investors · BiotechnologyRule 506(b)
▶$1.4MraisedAug 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin ScruggsDirector
- Joseph McMahonDirector
- Samuel FranklinDirector
- Christopher SimsExecutive Officer, Director
- Susan MahonyDirector
- Michael BironExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.4M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$3.1MraisedJul 2020 · 42 investors · BiotechnologyRule 506(b)
▶$3.1MraisedJul 2020 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Samuel FranklinDirector
- Joseph McMahonDirector
- Michael BironExecutive Officer, Director
- Christopher SimsExecutive Officer, Director
- Susan MahonyDirector
- Offering amount
- $3.1M
- Amount sold
- $3.1M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Fortis Life Sciences14 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Altis Labs10 shared keywordsAltis Labs provides a web-based platform that applies AI models to medical imaging data to generate reproducible predictions and quantifications for clinical trials. It serves biopharma and clinical trial teams, helping them detect treatment effects, inform trial design and go/no-go decisions, and generate evidence for reimbursement.
Oup8 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
IQVIA6 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with Altis Biosystems for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $913.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $343.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $294K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $256.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $245.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $223K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Altis Biosystems do?
- Altis Biosystems builds RepliGut®, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling. It serves pharmaceutical and life-science researchers as an alternative to animal studies and Caco-2 cell lines, offering ready-to-use kits and custom studies.
- Who are Altis Biosystems's investors?
- Altis Biosystems's investors include Atlanta Technology Angels, Central Texas Angel Network, Checkmate Capital Group LLC, IDEA NC, Johnson Venture Partners, VentureSouth, Hatteras Venture Partners.
- How much funding has Altis Biosystems raised?
- Altis Biosystems has disclosed $6.6M raised across 3 rounds.
- Where is Altis Biosystems headquartered?
- Altis Biosystems is headquartered in Durham, US.